Bydureon BCise was discontinued by its manufacturer AstraZeneca on October 28, 2024. This drug is no longer available in the United States. Discontinuation of Bydureon BCise was a business decision by ...
Data from Nearly 1,100 Patients in DURATION-1, -2 and -3 Trials Showed BYDUREON was Well-Tolerated ORLANDO, Fla.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company ...
INDIANAPOLIS, SAN DIEGO and WALTHAM, Mass., April 15, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), together with Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes, Inc. (Nasdaq: ALKS ...
WILMINGTON, Del., Jan. 10, 2018 /PRNewswire/ -- AstraZeneca today announced that BYDUREON ® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback